Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on June 7, 2016, reporting events occurring on June 1, 2016. The filing addresses amendments to executive employment agreements and the non-employee director compensation policy.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on compensation adjustments:
- CEO Salary: Reduced by $30,000 to $410,000 per annum.
- CSO Salary: Reduced by $260,000 to $490,000 per annum.
- Director Compensation: Annual compensation reduced from $200,000 to $100,000 per annum (effective July 1, 2016).
Material Changes
The primary material change is a significant reduction in cash compensation for top executives and the board of directors. The CEO's salary was cut by approximately 6.8%, while the Chief Scientific Officer's salary was cut by approximately 34.7%. Non-employee director compensation was cut by 50%.
Outlook, Risks, and Management Commentary
Management commentary is limited to the approval of these amendments by the Compensation Committee. The filing does not provide specific guidance, future outlook, or detailed risk factors beyond the implication of cost-cutting measures. No unusual items or contingencies are disclosed.
Investor Verification Checklist
- Verify the company name is Neuralstem, Inc., as the metadata reference to Palisade Bio, Inc. appears incorrect.
- Confirm the effective dates: Executive salary changes are effective June 1, 2016; director compensation changes are effective July 1, 2016.
- Review the company's cash position to understand the necessity of these significant salary reductions.
- Check subsequent filings for any further operational changes or financial updates related to these cost-saving measures.